Defendant
4 cases as defendant.
Ranbaxy Laboratories Limited (commonly "Ranbaxy") was an Indian generic pharmaceutical manufacturer headquartered in Gurgaon, Haryana, India. It was incorporated in 1961 (tracing to a 1937 medicine-distribution business) and listed on the BSE, NSE and Luxembourg exchanges from 1973. Daiichi Sankyo acquired a controlling (~63.9%) stake in 2008; Sun Pharmaceutical Industries agreed to acquire Ranbaxy in April 2014 and the merger completed in 2015, after which Ranbaxy was delisted and absorbed into Sun Pharma. Reported 2012 consolidated sales were about US$2.3 billion with roughly 14,600 employees globally (other sources cite ~11,000 for 2012).
Operations. Ranbaxy developed, manufactured and marketed generic and branded-generic prescription medicines, over-the-counter products, active pharmaceutical ingredients and intermediates, with ground operations in dozens of countries, manufacturing sites in multiple countries, and US subsidiaries including Ranbaxy Inc., Ranbaxy Pharmaceuticals Inc. and Ohm Laboratories. Notable products included generic atorvastatin, the differentiated isotretinoin product Absorica, and Synriam, an anti-malarial. The company's later years were marked by US FDA import alerts and a 2013 US guilty plea with a US$500 million penalty over manufacturing and data-integrity issues.
Litigation posture. The tracked data show Ranbaxy as a pure defendant: 4 cases, 0 as plaintiff, all in the District of New Jersey. This is the profile of an operating company being sued, not a patent assertion entity. The suits are Hatch-Waxman/ANDA patent actions brought by innovator Jazz Pharmaceuticals, not NPE assertions, and they cluster in D.N.J. — the venue where Jazz's Xyrem cases were consolidated — rather than a plaintiff-friendly NPE venue such as the Eastern District of Texas.
Notable cases. All four tracked matters are captioned Jazz Pharmaceuticals, Inc. v. Ranbaxy Laboratories Ltd. et al., filed in D.N.J. around July 2014, with additional related filings in 2015. They arise from Ranbaxy's ANDA (No. 203351) seeking approval for a generic sodium oxybate oral solution competing with Jazz's Xyrem. Jazz's public filings state the Ranbaxy litigation was settled on May 9, 2016, granting Ranbaxy a license to market a generic Xyrem on or after December 31, 2025, or earlier on certain events; related inter partes review petitions were terminated as part of that settlement.
Hatch-Waxman ANDA patent infringement action in the District of New Jersey. The multi-patent Xyrem complaint included US 7,668,730 and also asserted the '059, '988, '182, and '963 patents. The case was resolved short of trial and closed.
Jazz sued Ranbaxy entities in D.N.J. involving the '106 patent. The case was closed and later settled.
One of the consolidated D.N.J. Xyrem ANDA actions against Ranbaxy. A consolidation stipulation recites that this action alleged infringement of a patent list including US 6,780,889; it was consolidated with related Xyrem actions and resolved/terminated in the 2015-2018 window.
Filed after Ranbaxy's June 3, 2014 Paragraph IV notice; settled. The narrative lists this docket and/or 2:14-cv-04467 for the Ranbaxy suit.